Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:ALIM
- CUSIP: N/A
- Web: www.alimerasciences.com
Capitalization:- Market Cap: $95.29 million
- Outstanding Shares: 69,050,000
Average Prices:- 50 Day Moving Avg: $1.43
- 200 Day Moving Avg: $1.44
- 52 Week Range: $1.03 - $1.72
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.25
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $35.96 million
- Price / Sales: 2.65
- Book Value: ($0.70) per share
- Price / Book: -1.97
Profitability:- EBIDTA: ($16,780,000.00)
- Net Margins: -68.58%
- Return on Assets: -36.39%
Debt:- Debt-to-Equity Ratio: -0.72%
- Current Ratio: 4.63%
- Quick Ratio: 4.51%
Misc:- Average Volume: 258,670 shs.
- Beta: 2.22
- Short Ratio: 1.77
Frequently Asked Questions for Alimera Sciences (NASDAQ:ALIM)
What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
How were Alimera Sciences' earnings last quarter?
Alimera Sciences, Inc. (NASDAQ:ALIM) issued its earnings results on Wednesday, August, 2nd. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million for the quarter, compared to analyst estimates of $10.20 million. Alimera Sciences's revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) earnings per share. View Alimera Sciences' Earnings History.
When will Alimera Sciences make its next earnings announcement?
Where is Alimera Sciences' stock going? Where will Alimera Sciences' stock price be in 2017?
3 brokerages have issued 1 year price targets for Alimera Sciences' shares. Their forecasts range from $3.00 to $5.00. On average, they expect Alimera Sciences' stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Alimera Sciences.
What are analysts saying about Alimera Sciences stock?
Here are some recent quotes from research analysts about Alimera Sciences stock:
- 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (9/8/2017)
- 2. Cowen and Company analysts commented, "Positive Iluvien results were published in the journal Eye" for the treatment of DME." (7/25/2017)
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include Kadmon Holdings (KDMN), Kamada (KMDA), Vericel Corporation (VCEL), Peregrine Pharmaceuticals (PPHM), MediWound (MDWD), VIVUS (VVUS), Opiant Pharmaceuticals (OPNT), Cardiome Pharma Corporation (CRME), KalVista Pharmaceuticals (KALV), Chiasma (CHMA), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX), Sonoma Pharmaceuticals (SNOA), Catalyst Biosciences (CBIO), Onconova Therapeutics (ONTX), Argos Therapeutics (ARGS) and Auxilium Pharmaceuticals (AUXL).
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the folowing people:
- Richard S. Eiswirth Jr., President, Chief Financial Officer
- Rich Cockrell, President
- C. Daniel Myers, Chief Executive Officer
- Kenneth E. Green Ph.D., Senior Vice President, Chief Scientific Officer
- David R. Holland, Senior Vice President - Sales and Marketing
- Philip Ashman, Senior Vice President, European Managing Director
- Mark J. Brooks, Independent Director
- Brian K. Halak Ph.D., Independent Director
- Peter J. Pizzo III, Independent Director
Who owns Alimera Sciences stock?
Alimera Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Palo Alto Investors LLC (4.60%), Vanguard Group Inc. (2.47%), JW Asset Management LLC (1.49%), Goldman Sachs Group Inc. (0.46%), Parkwood LLC (0.35%) and Stonepine Capital Management LLC (0.28%). Company insiders that own Alimera Sciences stock include C Daniel Myers, James E Flynn, LP Bavp, Richard S Eiswirth Jr and Richard S Eiswirth, Jr. View Institutional Ownership Trends for Alimera Sciences.
Who sold Alimera Sciences stock? Who is selling Alimera Sciences stock?
Who bought Alimera Sciences stock? Who is buying Alimera Sciences stock?
How do I buy Alimera Sciences stock?
Shares of Alimera Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alimera Sciences' stock price today?
One share of Alimera Sciences stock can currently be purchased for approximately $1.38.
MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Alimera Sciences (NASDAQ:ALIM)Earnings History by Quarter for Alimera Sciences (NASDAQ ALIM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.05) | | | | | N/A |  |
| 8/2/2017 | Q2 2017 | ($0.05) | ($0.04) | $10.20 million | $10.40 million | View | Listen | |
| 5/8/2017 | Q1 2017 | ($0.08) | ($0.10) | $8.80 million | $6.62 million | View | Listen | |
| 3/1/2017 | Q4 2016 | ($0.07) | ($0.10) | $10.60 million | $10.70 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.11) | ($0.16) | $10.53 million | $8.30 million | View | N/A | |
| 8/3/2016 | Q2 | ($0.19) | ($0.17) | $8.42 million | $3.80 million | View | N/A | |
| 5/4/2016 | Q1 | ($0.19) | ($0.22) | $5.83 million | $5.80 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.22) | ($0.21) | $6.96 million | $6.90 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.22) | ($0.25) | $6.49 million | $5.80 million | View | Listen | |
| 5/7/2015 | Q115 | ($0.24) | ($0.27) | $3.90 million | $3.90 million | View | N/A | |
| 3/4/2015 | Q414 | ($0.16) | ($0.28) | $5.11 million | $1.70 million | View | N/A | |
| 11/6/2014 | Q314 | ($0.70) | ($0.22) | $3.75 million | $2.40 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.23) | ($0.15) | $2.70 million | $2.19 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.25) | ($0.20) | $1.15 million | $2.08 million | View | N/A | |
| 2/27/2014 | Q413 | ($0.29) | ($0.24) | $0.75 million | $0.94 million | View | N/A | |
| 11/11/2013 | Q313 | ($0.30) | ($0.26) | $0.38 million | $0.76 million | View | N/A | |
| 8/12/2013 | Q2 2013 | ($0.24) | ($0.30) | $3.00 million | | View | N/A | |
| 5/9/2013 | Q1 2013 | ($0.26) | ($0.27) | | | View | N/A | |
| 3/21/2013 | Q4 2012 | ($0.23) | ($0.17) | | | View | N/A | |
| 11/7/2012 | Q312 | ($0.19) | ($0.17) | | | View | N/A | |
| 3/8/2012 | | ($0.24) | ($0.19) | | | View | N/A | |
| 11/3/2011 | | ($0.19) | ($0.21) | | | View | N/A | |
| 8/4/2011 | | ($0.18) | ($0.17) | | | View | N/A | |
| 5/5/2011 | | ($0.20) | ($0.15) | | | View | N/A | |
| 2/10/2011 | | ($0.22) | ($0.20) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Alimera Sciences (NASDAQ:ALIM)Current Year EPS Consensus Estimate: $-0.21 EPS
Next Year EPS Consensus Estimate: $-0.08 EPS
Dividend History for Alimera Sciences (NASDAQ:ALIM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Alimera Sciences (NASDAQ:ALIM)Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 37.20%
Insider Trades by Quarter for Alimera Sciences (NASDAQ:ALIM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/10/2017 | C. Daniel Myers | CEO | Sell | 21,172 | $1.39 | $29,429.08 | |
| 9/15/2016 | Richard S Eiswirth Jr | Insider | Sell | 51,471 | $1.51 | $77,721.21 | |
| 4/21/2016 | L.P. Bavp | Major Shareholder | Sell | 478,673 | $2.59 | $1,239,763.07 | |
| 12/16/2015 | Richard S. Eiswirth, Jr. | CFO | Sell | 46,669 | $2.31 | $107,805.39 | |
| 12/8/2015 | James E Flynn | Insider | Buy | 272,249 | $3.01 | $819,469.49 | |
| 12/3/2015 | James E Flynn | Insider | Buy | 243,252 | $3.00 | $729,756.00 | |
| 10/30/2015 | James E Flynn | Insider | Buy | 16,542 | $3.00 | $49,626.00 | |
| 10/28/2015 | James E Flynn | Insider | Buy | 59,342 | $3.00 | $178,026.00 | |
| 10/26/2015 | James E Flynn | Insider | Buy | 60,364 | $3.00 | $181,092.00 | |
| 10/21/2015 | James E Flynn | Major Shareholder | Buy | 160,684 | $3.00 | $482,052.00 | |
| 10/20/2015 | James E Flynn | Major Shareholder | Buy | 100,130 | $3.00 | $300,390.00 | |
| 10/19/2015 | James E Flynn | Major Shareholder | Buy | 129,226 | $2.92 | $377,339.92 | |
| 10/15/2015 | Richard S. Eiswirth, Jr. | CFO | Sell | 13,625 | $2.69 | $36,651.25 | |
| 10/9/2015 | James E Flynn | Insider | Buy | 321,785 | $2.42 | $778,719.70 | |
| 9/3/2015 | Calvin W Roberts | Director | Buy | 6,424 | $3.00 | $19,272.00 | |
| 8/21/2015 | Kenneth Green | SVP | Sell | 20,000 | $3.29 | $65,800.00 | |
| 8/17/2015 | Kenneth Green | SVP | Sell | 20,000 | $3.90 | $78,000.00 | |
| 6/26/2015 | L.P. Bavp | Major Shareholder | Sell | 1,024 | $5.00 | $5,120.00 | |
| 6/19/2015 | L.P. Bavp | Major Shareholder | Sell | 5,568 | $5.00 | $27,840.00 | |
| 5/1/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $4.37 | $8,740.00 | |
| 4/27/2015 | L.P. Bavp | Major Shareholder | Sell | 3,114 | $5.02 | $15,632.28 | |
| 4/23/2015 | L.P. Bavp | Major Shareholder | Sell | 4,362 | $5.00 | $21,810.00 | |
| 4/20/2015 | L.P. Bavp | Major Shareholder | Sell | 30,300 | $5.03 | $152,409.00 | |
| 4/15/2015 | L.P. Bavp | Major Shareholder | Sell | 35,800 | $5.03 | $180,074.00 | |
| 4/14/2015 | L.P. Bavp | Major Shareholder | Sell | 18,400 | $5.01 | $92,184.00 | |
| 4/13/2015 | L.P. Bavp | Major Shareholder | Sell | 100 | $5.00 | $500.00 | |
| 3/6/2015 | Richard S Eiswirth Jr | CFO | Buy | 10,000 | $4.84 | $48,400.00 | |
| 3/2/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $5.21 | $10,420.00 | |
| 1/2/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $5.51 | $11,020.00 | |
| 1/2/2015 | David Holland | SVP | Sell | 5,000 | $5.56 | $27,800.00 | |
| 12/1/2014 | C. Daniel Myers | CEO | Sell | 2,000 | $5.99 | $11,980.00 | |
| 12/1/2014 | David Holland | SVP | Sell | 5,000 | $5.71 | $28,550.00 | |
| 10/27/2014 | L.P. Bavp | Major Shareholder | Sell | 57,918 | $6.34 | $367,200.12 | |
| 10/1/2014 | C. Daniel Myers | CEO | Sell | 2,000 | $5.42 | $10,840.00 | |
| 10/1/2014 | David Holland | SVP | Sell | 5,000 | $5.26 | $26,300.00 | |
| 10/1/2014 | Patrick Lee | Major Shareholder | Sell | 621,191 | $5.42 | $3,366,855.22 | |
| 9/30/2014 | Patrick Lee | Major Shareholder | Sell | 354,062 | $5.42 | $1,919,016.04 | |
| 9/29/2014 | Patrick Lee | Major Shareholder | Sell | 240,662 | $5.47 | $1,316,421.14 | |
| 9/11/2014 | L.P. Bavp | Major Shareholder | Sell | 2,816 | $6.25 | $17,600.00 | |
| 9/4/2014 | L.P. Bavp | Major Shareholder | Sell | 39,500 | $6.33 | $250,035.00 | |
| 8/29/2014 | L.P. Bavp | Major Shareholder | Sell | 7,400 | $6.27 | $46,398.00 | |
| 8/28/2014 | L.P. Bavp | Major Shareholder | Sell | 3,000 | $6.27 | $18,810.00 | |
| 8/1/2014 | David Holland | SVP | Sell | 5,000 | $5.64 | $28,200.00 | |
| 7/1/2014 | David Holland | SVP | Sell | 5,000 | $6.02 | $30,100.00 | |
| 5/1/2014 | David Holland | SVP | Sell | 5,000 | $5.93 | $29,650.00 | |
| 3/4/2014 | C. Daniel Myers | CEO | Sell | 22,775 | $7.10 | $161,702.50 | |
| 3/4/2014 | David Holland | SVP | Sell | 10,000 | $6.84 | $68,400.00 | |
| 3/4/2014 | Susan Caballa | Insider | Sell | 8,931 | $7.01 | $62,606.31 | |
| 1/16/2014 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 296,760 | $6.39 | $1,896,296.40 | |
| 7/17/2013 | Polaris Venture Management Co | Insider | Sell | 122,937 | $4.80 | $590,097.60 | |
| 6/20/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 10,516 | $5.01 | $52,685.16 | |
| 6/19/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 55,278 | $5.39 | $297,948.42 | |
| 6/18/2013 | Polaris Venture Management Co | Insider | Sell | 37,063 | $5.44 | $201,622.72 | |
| 6/17/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 126,709 | $5.29 | $670,290.61 | |
| 6/11/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 5,337 | $5.00 | $26,685.00 | |
| 5/17/2013 | David Holland | SVP | Sell | 30,000 | $4.13 | $123,900.00 | |
| 5/16/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 44,242 | $4.60 | $203,513.20 | |
| 12/13/2012 | Peter J Pizzo III | Director | Buy | 5,000 | $1.44 | $7,200.00 | |
| 12/3/2012 | C. Daniel Myers | CEO | Sell | 7,700 | $1.95 | $15,015.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Alimera Sciences (NASDAQ:ALIM)
Latest Headlines for Alimera Sciences (NASDAQ:ALIM)
| Source: |
|
| Date | Headline |
|---|
 | Alimera Sciences to Present at the Sidoti & Company Fall 2017 ... - GlobeNewswire (press release)
globenewswire.com - September 19 at 3:43 PM |
 | Alimera Sciences to Present at the Sidoti & Company Fall 2017 Conference
finance.yahoo.com - September 19 at 3:43 PM |
| Alimera Sciences, Inc. (ALIM)
finance.yahoo.com - September 18 at 9:10 PM |
| Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global Investment ... - GlobeNewswire (press release)
globenewswire.com - September 13 at 4:53 PM |
| Alimera Sciences Announces ILUVIEN® now available in Ireland - GlobeNewswire (press release)
globenewswire.com - September 13 at 4:53 PM |
 | Alimera Sciences Announces ILUVIEN® now available in Ireland - Nasdaq
www.nasdaq.com - September 12 at 8:59 PM |
| Alimera Sciences Announces ILUVIEN® now available in Ireland
finance.yahoo.com - September 12 at 8:59 PM |
| Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global Investment ... - Nasdaq
www.nasdaq.com - September 11 at 9:38 PM |
| Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 11 at 4:35 PM |
| ETFs with exposure to Alimera Sciences, Inc. : September 9, 2017
finance.yahoo.com - September 9 at 2:15 AM |
 | Alimera Sciences, Inc. (ALIM) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - September 8 at 5:02 PM |
| Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017
finance.yahoo.com - September 7 at 3:43 PM |
| Alimera Sciences Announces 9 Clinical Presentations and a ... - GlobeNewswire (press release)
globenewswire.com - September 5 at 10:10 PM |
| Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congress
finance.yahoo.com - September 5 at 5:10 PM |
| Alimera Sciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 1 at 1:17 AM |
| Alimera Sciences, Inc. (ALIM) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - August 30 at 11:16 AM |
 | BRIEF-Alimera Sciences signs agreement for distribution of Iluvien in France
www.reuters.com - August 30 at 2:09 AM |
| Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in France - GlobeNewswire (press release)
globenewswire.com - August 29 at 9:08 PM |
| Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in France
finance.yahoo.com - August 29 at 9:08 PM |
| Alimera Sciences, Inc. (ALIM) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - August 29 at 5:18 PM |
| Zacks Investment Research Downgrades Alimera Sciences, Inc. (ALIM) to Sell
www.americanbankingnews.com - August 23 at 4:46 PM |
| Alimera Sciences, Inc. (ALIM) Downgraded by Zacks Investment Research
www.americanbankingnews.com - August 17 at 4:54 PM |
| Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting - Nasdaq
www.nasdaq.com - August 9 at 8:58 PM |
| Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting
finance.yahoo.com - August 9 at 3:56 PM |
| Alimera Sciences' CEO Dan Myers to Present US Real-World ILUVIEN® Post-Marketing Data During Ophthalmology ... - Nasdaq
www.nasdaq.com - August 9 at 1:23 AM |
| Alimera Sciences' CEO Dan Myers to Present US Real-World ILUVIEN® Post-Marketing Data During Ophthalmology ... - GlobeNewswire (press release)
globenewswire.com - August 8 at 2:43 AM |
| Alimera Sciences' CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017
finance.yahoo.com - August 7 at 4:40 PM |
| HC Wainwright Reiterates "$5.00" Price Target for Alimera Sciences, Inc. (NASDAQ:ALIM)
www.americanbankingnews.com - August 6 at 10:26 PM |
 | Alimera Sciences' (ALIM) CEO Dan Myers on Q2 2017 Results ... - Seeking Alpha
seekingalpha.com - August 6 at 8:31 PM |
| Alimera Sciences, Inc. (NASDAQ:ALIM) Given a $3.00 Price Target by Cowen and Company Analysts
www.americanbankingnews.com - August 6 at 6:28 PM |
| Edited Transcript of ALIM earnings conference call or presentation 3-Aug-17 1:00pm GMT
finance.yahoo.com - August 5 at 3:32 PM |
| Alimera Sciences reports 2Q loss
finance.yahoo.com - August 3 at 4:43 PM |
| Alimera Sciences, Inc. (NASDAQ:ALIM) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - August 3 at 3:39 PM |
| Alimera Sciences Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 3 at 1:41 AM |
| Alimera Sciences Reports Second Quarter 2017 Financial Results
www.nasdaq.com - August 2 at 8:40 PM |
| Comparing Alimera Sciences (NASDAQ:ALIM) & Sinovac Biotech (SVA)
www.americanbankingnews.com - July 28 at 7:49 AM |
| BRIEF-Alimera Sciences announces real-world audit data supporting positive benefits of iluvien treatment
www.reuters.com - July 26 at 1:34 AM |
| Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment - GlobeNewswire (press release)
globenewswire.com - July 25 at 8:34 PM |
| Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment
finance.yahoo.com - July 25 at 8:34 PM |
| Alimera Sciences, Inc. (ALIM) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:06 AM |
| Alimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017
finance.yahoo.com - July 24 at 1:26 PM |
 | Alimera Sciences (ALIM) Says MHRA Has Given Final Approval to Reduce Size of its ILUVIEN Registry Safety Study - StreetInsider.com
www.streetinsider.com - July 20 at 5:05 PM |
| Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the UK - Nasdaq
www.nasdaq.com - July 19 at 4:54 PM |
| Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the U.K.
finance.yahoo.com - July 19 at 4:54 PM |
| Leading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at ... - Nasdaq
www.nasdaq.com - July 18 at 5:10 PM |
| Zacks Investment Research Lowers Alimera Sciences, Inc. (NASDAQ:ALIM) to Hold
www.americanbankingnews.com - July 13 at 7:14 PM |
| ETFs with exposure to Alimera Sciences, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 4:30 PM |
| Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN® - Nasdaq
www.nasdaq.com - July 12 at 4:09 PM |
| Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®
finance.yahoo.com - July 12 at 4:09 PM |
 | BRIEF-Psivida out-licenses EMEA rights for Durasert three-year treatment for posterior segment Uveitis
www.businessinsider.com - July 11 at 5:00 PM |
Alimera Sciences (ALIM) Chart for Friday, September, 22, 2017
